Ying Wang1, Weihao Zhang, Ping Liu, Zhi Guo, Hong Ni. 1. Department of Interventional Therapy, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Abstract
OBJECTIVE: The aim of this study was to evaluate the effectiveness and safety of percutaneous interstitial implantation with (125)I seed under computed tomographic (CT) guidance for recurrent ovarian cancer (ROC). MATERIALS AND METHODS: A retrospective review was performed on 17 patients with ROC who were treated with (125)I seed brachytherapy. Treatment planning system was used preoperatively to determine the estimated seeds number and distribution; (125)I seeds were implanted into recurrent lesions under CT guidance. Therapeutic effectiveness and complications were noted during follow-up time. RESULTS: Months are counted from the time of (125)I seed brachytherapy, and the median duration of follow-up was 10.5 months (3-23 months). The objective response rates after 1, 3, 6, 12, and 18 months were 76.5%, 75.0%, 61.5%, 42.9%, and 40%, respectively. The pain relief rate was 61.5%, and the general living quality was improved dramatically. The median progression-free survival time was 5.4 months, the median overall survival time was 11.3 months, and the 1-year survival rate was 41.2%. Complications in this study were very mild; severe adverse events such as massive bleeding, intestinal fistula, and treatment-related deaths did not occur. CONCLUSIONS: Our initial experience showed that CT-guided (125)I seed interstitial implantation is safe and feasible in the treatment of patients with ROCs after multiple therapies.
OBJECTIVE: The aim of this study was to evaluate the effectiveness and safety of percutaneous interstitial implantation with (125)I seed under computed tomographic (CT) guidance for recurrent ovarian cancer (ROC). MATERIALS AND METHODS: A retrospective review was performed on 17 patients with ROC who were treated with (125)I seed brachytherapy. Treatment planning system was used preoperatively to determine the estimated seeds number and distribution; (125)I seeds were implanted into recurrent lesions under CT guidance. Therapeutic effectiveness and complications were noted during follow-up time. RESULTS: Months are counted from the time of (125)I seed brachytherapy, and the median duration of follow-up was 10.5 months (3-23 months). The objective response rates after 1, 3, 6, 12, and 18 months were 76.5%, 75.0%, 61.5%, 42.9%, and 40%, respectively. The pain relief rate was 61.5%, and the general living quality was improved dramatically. The median progression-free survival time was 5.4 months, the median overall survival time was 11.3 months, and the 1-year survival rate was 41.2%. Complications in this study were very mild; severe adverse events such as massive bleeding, intestinal fistula, and treatment-related deaths did not occur. CONCLUSIONS: Our initial experience showed that CT-guided (125)I seed interstitial implantation is safe and feasible in the treatment of patients with ROCs after multiple therapies.